AstraZeneca/Infinity’s Hsp90 Inhibitor Advances In GIST
This article was originally published in The Pink Sheet Daily
Executive Summary
Positive PFS data in patients treated with retaspimycin presented at ASCO; Phase III to start in third quarter.